Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of “Buy” by Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received an average recommendation of “Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.63.

A number of brokerages recently issued reports on TSHA. Chardan Capital reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, February 27th.

Institutional Trading of Taysha Gene Therapies

Hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its holdings in shares of Taysha Gene Therapies by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after purchasing an additional 11,390 shares during the last quarter. Geode Capital Management LLC grew its holdings in Taysha Gene Therapies by 23.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after buying an additional 682,273 shares in the last quarter. Wellington Management Group LLP bought a new stake in Taysha Gene Therapies in the 3rd quarter worth approximately $931,000. Barclays PLC raised its holdings in shares of Taysha Gene Therapies by 356.0% during the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after acquiring an additional 193,046 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after acquiring an additional 150,647 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Down 3.2 %

TSHA opened at $1.22 on Friday. The firm’s 50 day simple moving average is $1.63 and its two-hundred day simple moving average is $1.88. The company has a market capitalization of $250.10 million, a PE ratio of 1.94 and a beta of 0.96. Taysha Gene Therapies has a 1-year low of $1.17 and a 1-year high of $4.32. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. As a group, equities analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.